Completed PHASE1 INTERVENTIONAL 4-arm NCT03801902

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

Sponsor: NRG Oncology

Conditions Locally Advanced Lung Non-Small Cell Carcinoma Locally Recurrent Lung Non-Small Cell Carcinoma Stage II Lung Cancer AJCC v8 Stage III Lung Cancer AJCC v8 Unresectable Lung Non-Small Cell Carcinoma

Interventions Accelerated Hypofractionated Radiation Therapy Biospecimen Collection Computed Tomography Durvalumab Magnetic Resonance Imaging of the Brain with and without Contrast Monalizumab Oleclumab Radiation Therapy

Updated 55 times since 2019 Last updated: Sep 6, 2025 Started: Oct 28, 2019 Primary completion: Oct 26, 2021 Completion: Sep 4, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03801902, this PHASE1 trial focuses on Locally Advanced Lung Non-Small Cell Carcinoma and Locally Recurrent Lung Non-Small Cell Carcinoma and remains completed. Sponsored by NRG Oncology, it has been updated 55 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

55 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE1
Jul 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
May 2025 — Jul 2025 [monthly]

Active Not Recruiting PHASE1
Jan 2025 — May 2025 [monthly]

Active Not Recruiting PHASE1

Status: Suspended → Active Not Recruiting

▶ Show 50 earlier versions

Dec 2024 — Jan 2025 [monthly]

Suspended PHASE1
Nov 2024 — Dec 2024 [monthly]

Suspended PHASE1

Status: Recruiting → Suspended
Sep 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1

Status: Suspended → Recruiting
Dec 2023 — Feb 2024 [monthly]

Suspended PHASE1
Nov 2023 — Dec 2023 [monthly]

Suspended PHASE1
Oct 2023 — Nov 2023 [monthly]

Suspended PHASE1
Sep 2023 — Oct 2023 [monthly]

Suspended PHASE1
Aug 2023 — Sep 2023 [monthly]

Suspended PHASE1
Jun 2023 — Aug 2023 [monthly]

Suspended PHASE1
Apr 2023 — Jun 2023 [monthly]

Suspended PHASE1
Mar 2023 — Apr 2023 [monthly]

Suspended PHASE1
Feb 2023 — Mar 2023 [monthly]

Suspended PHASE1

Status: Active Not Recruiting → Suspended
Sep 2022 — Feb 2023 [monthly]

Active Not Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1
Jun 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE1
May 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE1
Apr 2022 — May 2022 [monthly]

Active Not Recruiting PHASE1
Feb 2022 — Apr 2022 [monthly]

Active Not Recruiting PHASE1
Jan 2022 — Feb 2022 [monthly]

Active Not Recruiting PHASE1
Dec 2021 — Jan 2022 [monthly]

Active Not Recruiting PHASE1
Sep 2021 — Dec 2021 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Jun 2021 — Sep 2021 [monthly]

Recruiting PHASE1
May 2021 — Jun 2021 [monthly]

Recruiting PHASE1
Apr 2021 — May 2021 [monthly]

Recruiting PHASE1
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Aug 2020 — Sep 2020 [monthly]

Recruiting PHASE1

Status: Suspended → Recruiting
Jul 2020 — Aug 2020 [monthly]

Suspended PHASE1
May 2020 — Jul 2020 [monthly]

Suspended PHASE1

Status: Recruiting → Suspended
Apr 2020 — May 2020 [monthly]

Recruiting PHASE1
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE1
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE1
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Jan 2020 [monthly]

Recruiting PHASE1
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE1
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE1
Sep 2019 — Oct 2019 [monthly]

Recruiting PHASE1
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE1
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE1
May 2019 — Jul 2019 [monthly]

Recruiting PHASE1

Status: Suspended → Recruiting
Feb 2019 — May 2019 [monthly]

Suspended PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Augusta, United States , Baltimore, United States , Bay City, United States , Bel Air, United States , Boise, United States , Caldwell, United States , City of Saint Peters, United States , Clarkston, United States , Columbia, United States and 34 more locations